Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Adaptimmune Therapeutics plc ADAP

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include... see more

Bullboard (NDAQ:ADAP)

View:
Post by whytestockson Aug 12, 2024 10:47am

Medical Tech and Biotech Stocks to Watch and the Treatments

NEWS: $ADAP Medical Tech and Biotech Stocks to Watch and the Treatments for Solid Tumors2024-08-12 10:10:00 ET August 12, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing ...more  
Post by whytestockson Aug 05, 2024 10:01pm

Adaptimmune to Report Q2 2024 Financial and Business Updates

Just In: $ADAP Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024 ...more  
Post by whytestockson Feb 21, 2024 4:15pm

Adaptimmune to Report Q4 and Full Year 2023 Financial and Bu

Breaking News: $ADAP Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp ...more  
Post by hoffbagon Aug 24, 2022 6:05pm

Some giddy yapping here....

Will see how they go.  Expensive, but helpful treatment today.....maybe a future here.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities